Tirzepatide

Extended indication	Extension of indication to include chronic weight management, including weight loss and weight maintenance, for MOUNJARO.
Therapeutic value	No estimate possible yet
Registration phase	Registration application pending

Product

Active substance	Tirzepatide
Domain	Metabolism and Endocrinology
Reason of inclusion	Indication extension
Main indication	Other metabolism and Endocrinology
Extended indication	Extension of indication to include chronic weight management, including weight loss and weight maintenance, for MOUNJARO.
Proprietary name	Mounjaro
Manufacturer	Eli Lilly
Portfolio holder	Eli Lilly
Mechanism of action	Other, see general comments
Route of administration	Subcutaneous
Therapeutical formulation	Injection
Budgetting framework	Extramural (GVS)
Additional remarks	Gecombineerde GIP/GLP-1 agonist. Tirzepatide is één enkel molecuul.

Registration route	Centralised (EMA)
ATMP	No
Submission date	March 2023
Expected Registration	January 2024
Orphan drug	No
Registration phase	Registration application pending

Therapeutic value	No estimate possible yet

There is currently nothing known about the expected patient volume.

References	https://www.farmacotherapeutischkompas.nl
Additional remarks	De kosten voor een 0,5 ml injectievloeistof bevattende Tirzepatide 10 mg/ml bedragen € 102,05.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.